A systematic review of gene editing clinical trials
Eshka, S. F. A.; Bahador, M.; Gordan, M. M.; Karbasi, S.; Tabar, Z. M.; Basiri, M.
Show abstract
Gene editing technologies such as zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR) have revolutionized genetic engineering and now are being used in clinical gene therapy. We systematically reviewed gene editing clinical trials from ClinicalTrials.gov using a searching strategy that included all different gene editing technologies, followed by two rounds of independent assessment based on the inclusion and exclusion criteria, data extraction, and review of the background publications. 76 trials met our inclusion criteria including 30 studies on genetically engineered T-cell therapies for cancer, 19 studies on virus infections, and 26 studies on monogenic diseases. We have also analyzed the proportions to which different gene editing and gene delivery methods are used. We observed a growing trend of registered CRISPR-based trials indicating a raising interest in developing new therapeutic methods based on this technology. Overall, our study showed that there are promising phase-I and -II trials testing the safety and feasibility of gene editing in different clinical settings.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Genetic landscape of rare autoinflammatory disease variants in Qatar and Middle Eastern populations through the integration of whole-genome and exome datasets 90%
- Whole-genome sequencing of Vero E6 (C1008) and comparative analysis of four Vero cell sublines 90%
- Deletion of FUNDC2 and CMC4 on chromosome Xq28 is sufficient to cause hypergonadotropic hypogonadism in men 90%
Similar papers in this journal
- Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis 90%
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 89%
- Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic 89%
Similar papers in this journal
- Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia 91%
- Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1 89%
- Repressing PTBP1 is incapable to convert reactive astrocytes to dopaminergic neurons in a mouse model of Parkinson's disease 89%
Similar papers in this journal
- Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapy 89%
- Research productivity and collaboration of the NIH-funded HIV Vaccine Trials Network: a bibliometric analysis 89%
- Dynamics of anti-Spike IgG antibody titer after the third BNT162b2 COVID-19 vaccination in the Japanese health care workers 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.